185 related articles for article (PubMed ID: 24219778)
21. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
[TBL] [Abstract][Full Text] [Related]
22. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S; Yamane Y; Tsukamoto S; Azuma H; Nagao S; Murai N; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem; 2021 Jun; 39():116137. PubMed ID: 33930844
[TBL] [Abstract][Full Text] [Related]
24. Optimization of an Imidazo[1,2-
McCoull W; Boyd S; Brown MR; Coen M; Collingwood O; Davies NL; Doherty A; Fairley G; Goldberg K; Hardaker E; He G; Hennessy EJ; Hopcroft P; Hodgson G; Jackson A; Jiang X; Karmokar A; Lainé AL; Lindsay N; Mao Y; Markandu R; McMurray L; McLean N; Mooney L; Musgrove H; Nissink JWM; Pflug A; Reddy VP; Rawlins PB; Rivers E; Schimpl M; Smith GF; Tentarelli S; Travers J; Troup RI; Walton J; Wang C; Wilkinson S; Williamson B; Winter-Holt J; Yang D; Zheng Y; Zhu Q; Smith PD
J Med Chem; 2021 Sep; 64(18):13524-13539. PubMed ID: 34478292
[TBL] [Abstract][Full Text] [Related]
25. Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.
Papa P; Whitefield B; Mortensen DS; Cashion D; Huang D; Torres E; Parnes J; Sapienza J; Hansen J; Correa M; Delgado M; Harris R; Hegde S; Norris S; Bahmanyar S; Plantevin-Krenitsky V; Liu Z; Leftheris K; Kulkarni A; Bennett B; Hur EM; Ringheim G; Khambatta G; Chan H; Muir J; Blease K; Burnett K; LeBrun L; Morrison L; Celeridad M; Khattri R; Cathers BE
J Med Chem; 2021 Aug; 64(16):11886-11903. PubMed ID: 34355886
[TBL] [Abstract][Full Text] [Related]
26. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase.
Ling L; Kung HJ
Mol Cell Biol; 1995 Dec; 15(12):6582-92. PubMed ID: 8524223
[TBL] [Abstract][Full Text] [Related]
27. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
28. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
29. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
Achary R; Mathi GR; Lee DH; Yun CS; Lee CO; Kim HR; Park CH; Kim P; Hwang JY
Bioorg Med Chem Lett; 2017 May; 27(10):2185-2191. PubMed ID: 28385505
[TBL] [Abstract][Full Text] [Related]
30. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.
Sather S; Kenyon KD; Lefkowitz JB; Liang X; Varnum BC; Henson PM; Graham DK
Blood; 2007 Feb; 109(3):1026-33. PubMed ID: 17047157
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
32. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
33. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL; Sather S; Zhang D; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2014 Aug; 57(16):7031-41. PubMed ID: 25068800
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
35. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
[TBL] [Abstract][Full Text] [Related]
37. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Zhang X; Raghavan S; Ihnat M; Thorpe JE; Disch BC; Bastian A; Bailey-Downs LC; Dybdal-Hargreaves NF; Rohena CC; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2014 Jul; 22(14):3753-72. PubMed ID: 24890652
[TBL] [Abstract][Full Text] [Related]
38. Mer receptor tyrosine kinase signaling participates in platelet function.
Chen C; Li Q; Darrow AL; Wang Y; Derian CK; Yang J; de Garavilla L; Andrade-Gordon P; Damiano BP
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1118-23. PubMed ID: 15130911
[TBL] [Abstract][Full Text] [Related]
39. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
40. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]